- Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
- Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
- Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
- Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024
- Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors
- Elevation Oncology to Participate in Upcoming Investor Conferences
- Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan
More ▼
Key statistics
On Friday, Elevation Oncology Inc (ELEV:NSQ) closed at 3.70, -37.18% below its 52-week high of 5.89, set on May 26, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.81 |
---|---|
High | 4.13 |
Low | 3.69 |
Bid | 3.03 |
Offer | 4.53 |
Previous close | 3.70 |
Average volume | 1.13m |
---|---|
Shares outstanding | 54.64m |
Free float | 50.77m |
P/E (TTM) | -- |
Market cap | 202.16m USD |
EPS (TTM) | -1.53 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼